 | This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
 Logo of Antibe Therapeutics | |
| Company type | Publicly traded corporation |
|---|---|
| TSX: ATE | |
| Industry | Pharmaceuticals |
| Founded | 1 January 2010
 |
| Headquarters | Toronto , Canada |
Key people | Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Scientific Officer; Joseph Stauffer, Chief Medical Officer |
| Website |
www |
Antibe Therapeutics is a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. [1] Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine. [2]
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul. [3]
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials. [4]
Products
 | It has been suggested that this section be
split out into another article titled
Otenaproxesul. (
Discuss) (February 2021) |
The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body. [5] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation. [6]
Antibe's lead drug, Otenaproxesul (formerly ATB-346, now known by its International Nonproprietary Name), is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). Otenaproxesul is being developed as a safer non-opiod analgesic for acute pain. Antibe is targeting the post-operative pain market and plans to broaden its application to include migraines, dysmenorrhea and dental pain. Unlike standard naproxen, Otenaproxesul does not induce damage to the gastrointestinal tract. [7]
In May 2014, the company announced that it had completed pre-clinical studies on Otenaproxesul. [8] In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials. [9] In mid-January 2015, the company announced that clinical trials for Otenaproxesul were being suspended due to safety concerns; clinical trials were restarted in March 2015. [10]
On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B gastrointestinal safety study for Otenaproxesul. [11] On June 1, 2020, Antibe announced positive results for Otenaproxesul in its final Phase 2 trial – a dose ranging, efficacy study. [12] The company's second drug, an opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2023. [13]
On November 12, 2020, Antibe Therapeutics has moved to the TSX. In February 2021, Antibe announced a deal with Nuance Pharma, a Chinese pharmaceutical company, entitling them to $100 million in funding, with $20 million upfront. [14]
People
Antibe's science advisory board: [15]
- Andre G. Buret, Professor, University of Calgary, Canada
- Giuseppe Cirino, PhD, Professor, University of Naples, Italy
- Gilberto de Nucci, MD, PhD, Professor, University of Sao Paulo, Brazil
- Peter B. Ernst, DVM, PhD, Professor, UCSD, San Diego, USA
- Derek Gilroy, PhD, Professor, University College, London, UK
- Richard H. Hunt, MD, Emeritus Professor, McMaster University, Canada
- Louis Ignarro, PhD Professor, UCLA, Los Angeles, USA - 1998 Nobel Prize Laureate in Medicine
- Daniel K. Podolsky, MD, President, University of Texas Southwestern Medical Center, USA
- William Sessa, PhD, Professor, Yale University, USA
- Philip M. Sherman, MD, Professor, University of Toronto, Canada
Antibe's board of directors: [16]
- Chair - Walt Macnee, Vice Chair, MasterCard International [17]
- Roderick Flower, Professor Emeritus, Barts and The London School of Medicine and Dentistry
- Dan Legault, CEO, Antibe Therapeutics
- Robert Hoffman, former CFO, Heron Therapeutics; Director, public biotechnology companies
- Amal Khouri, VP Business Development, Knight Therapeutics [18]
- Jennifer McNealey, VP Investor Relations and Strategy, Calithera Biosciences
- John L. Wallace, Chief Scientific Officer, Antibe Therapeutics
- Yung Wu, CEO, MaRS Discovery District [19]
References
- ^ "Antibe Therapeutics". Archived from the original on 2021-11-17. Retrieved 2021-11-23.
- ^ "Stocks". Bloomberg News. Archived from the original on 2017-12-17. Retrieved 2021-11-23.
- ^ "Antibe's Non-Opioid Pain Drug Otenaproxesul Looks Good in Phase IIb Trials". American Council on Science and Health. August 5, 2020. Archived from the original on June 26, 2021. Retrieved November 23, 2021.
- ^ "Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain". American Council on Science and Health. 2021-03-21. Archived from the original on 2023-06-01. Retrieved 2023-06-01.
- ^ "Why Hydrogen Sulfide? – Antibe Therapeutics". 21 August 2019. Archived from the original on 2021-08-12. Retrieved 2021-11-23.
- ^ Bhatia, Madhav (2015). "H2S and Inflammation: An Overview". Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide. Handbook of Experimental Pharmacology. Vol. 230. pp. 165–180. doi: 10.1007/978-3-319-18144-8_8. ISBN 978-3-319-18143-1. PMID 26162834.
- ^ British Journal of Pharmacology Wallace, John L.; Nagy, Peter; Feener, Troy D.; Allain, Thibault; Ditrói, Tamás; Vaughan, David J.; Muscara, Marcelo N.; Nucci, Gilberto; Buret, Andre G. (February 2019). "A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug". Br J Pharmacol. 177 (4): 769–777. doi: 10.1111/bph.14641. PMC 7024706. PMID 30834513.
- ^ https://www.wsj.com/article/PR-CO-20140505-901386.html[ permanent dead link]
- ^ "Antibe Therapeutics Announces First Human Dose of ATB-346 in Phase I Clinical Trial - MarketWatch". Archived from the original on 2014-07-14. Retrieved 2014-06-27.
- ^ "Antibe Therapeutics Provides an Update on its Data Review and Corporate Strategy – Antibe Therapeutics". 11 March 2015. Archived from the original on 2021-04-16. Retrieved 2021-11-23.
- ^ "Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346 – Antibe Therapeutics". 20 March 2018. Archived from the original on 2021-04-16. Retrieved 2021-11-23.
- ^ "Antibe Therapeutics Announces Positive Top-Line Data from Phase 2B Dose-Ranging, Efficacy Study for ATB-346 – Antibe Therapeutics". June 2020. Archived from the original on 2021-02-25. Retrieved 2021-11-23.
- ^ "Antibe Therapeutics Provides Corporate Update – Antibe Therapeutics". 4 August 2020. Archived from the original on 2021-05-28. Retrieved 2021-11-23.
- ^ "Antibe Therapeutics inks licensing deal with Nuance Pharma". www.biospectrumasia.com.
- ^ "Scientific Advisory Board – Antibe Therapeutics". 22 July 2019. Archived from the original on 2021-08-12. Retrieved 2021-11-23.
- ^ "Board of Directors – Antibe Therapeutics". 28 August 2019. Archived from the original on 2021-08-13. Retrieved 2021-11-23.
- ^ "Mastercard Incorporated - Investor Relations". investor.mastercard.com. Archived from the original on 2021-11-22. Retrieved 2021-11-23.
- ^ "Knight Therapeutics – Building a leading specialty pharmaceutical company". Archived from the original on 2020-09-25. Retrieved 2021-11-23.
- ^ "About MaRS". MaRS Discovery District. Archived from the original on 2021-11-19. Retrieved 2021-11-23.
External links
- Biotechnology Focus: The Need for a Safer NSAID: Can Antibe Therapeutics Deliver One? [1]
- Third International Conference on Medical & Biological Uses of Hydrogen Sulfide Third International Conference on Hydrogen Sulfide in Biology and Medicine (H2S 2014)